The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance

Oncotarget

Volumn 7, Issue 19, 2016, Pages 28273-28285

  Quackenbush, Kevin S ^a   Bagby, Stacey ^a   Tai, W M ^a,b   Messersmith, Wells A ^a   Schreiber, Anna ^a   Greene, Justin ^a   Kim, Jihye ^a   Wang, Guoliang ^a   Purkey, Alicia ^a   Pitts, Todd M ^a   Nguyen, Anna ^a   Gao, Dexiang ^a   Blatchford, Patrick ^a   Capasso, Anna ^a   Schuller, Alwin G ^c   Eckhardt, S Gail ^a   Arcaroli, John J ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^c ASTRAZENECA   (United Kingdom)

Author keywords

CRC; IRN; NuMA; PDTX; WNT

Indexed keywords

AXIN; AXIN2; AZ 1366; BETA CATENIN; IRINOTECAN; NUCLEAR PROTEIN; PROTEIN NUMA; TANKYRASE; TANKYRASE INHIBITOR; UNCLASSIFIED DRUG; WNT PROTEIN; ANTINEOPLASTIC AGENT; AXIN2 PROTEIN, HUMAN; CAMPTOTHECIN; ENZYME INHIBITOR; TNKS PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER TISSUE; CELL PROLIFERATION; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESISTANCE; DRUG TISSUE LEVEL; ENZYME INHIBITION; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; M PHASE CELL CYCLE CHECKPOINT; MONOTHERAPY; MOUSE; NONHUMAN; PHARMACODYNAMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR XENOGRAFT; WESTERN BLOTTING; ADULT; AGED; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; COLORECTAL TUMOR; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; MALE; MIDDLE AGED; NUDE MOUSE;

ADULT; AGED; ANIMALS; ANTINEOPLASTIC AGENTS; AXIN PROTEIN; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MICE; MICE, NUDE; MIDDLE AGED; TANKYRASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84968718479     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8626     Document Type: Article

References (37)

1. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006; 127:469-480.
2. Barker N. Adult intestinal stem cells: critical drivers of epithelial homeostasis and regeneration. Nature reviews Molecular cell biology. 2014; 15:19-33.
3. Kimelman D, Xu W. beta-catenin destruction complex: insights and questions from a structural perspective. Oncogene. 2006; 25:7482-7491.
4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA. 2015; 65:5-29.
5. Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN, Vogelstein B, Kinzler KW. APC mutations occur early during colorectal tumorigenesis. Nature. 1992; 359:235-237.
6. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005; 434:843-850.
7. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487:330-337.
8. Dow LE, O'Rourke KP, Simon J, Tschaharganeh DF, van Es JH, Clevers H, Lowe SW. Apc Restoration Promotes Cellular Differentiation and Reestablishes Crypt Homeostasis in Colorectal Cancer. Cell. 2015; 161:1539-1552.
9. Lee E, Salic A, Kruger R, Heinrich R, Kirschner MW. The roles of APC and Axin derived from experimental and theoretical analysis of the Wnt pathway. PLoS biology. 2003; 1:E10.
10. Riffell JL, Lord CJ, Ashworth A. Tankyrase-targeted therapeutics: expanding opportunities in the PARP family. Nature reviews Drug discovery. 2012; 11:923-936.
11. Huang SM, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA, Charlat O, Wiellette E, Zhang Y, Wiessner S, Hild M, Shi X, Wilson CJ, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature. 2009; 461:614-620.
12. Chen B, Dodge ME, Tang W, Lu J, Ma Z, Fan CW, Wei S, Hao W, Kilgore J, Williams NS, Roth MG, Amatruda JF, Chen C, et al. Small molecule-mediated disruption of Wntdependent signaling in tissue regeneration and cancer. Nature chemical biology. 2009; 5:100-107.
13. Waaler J, Machon O, von Kries JP, Wilson SR, Lundenes E, Wedlich D, Gradl D, Paulsen JE, Machonova O, Dembinski JL, Dinh H, Krauss S. Novel synthetic antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth. Cancer research. 2011; 71:197-205.
14. Bao R, Christova T, Song S, Angers S, Yan X, Attisano L. Inhibition of tankyrases induces Axin stabilization and blocks Wnt signalling in breast cancer cells. PloS one. 2012; 7:e48670.
15. Waaler J, Machon O, Tumova L, Dinh H, Korinek V, Wilson SR, Paulsen JE, Pedersen NM, Eide TJ, Machonova O, Gradl D, Voronkov A, von Kries JP, et al. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. Cancer research. 2012; 72:2822-2832.
16. Lau T, Chan E, Callow M, Waaler J, Boggs J, Blake RA, Magnuson S, Sambrone A, Schutten M, Firestein R, Machon O, Korinek V, Choo E, et al. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth. Cancer research. 2013; 73:3132-3144.
17. Johannes JW, Almeida L, Barlaam B, Boriack-Sjodin PA, Casella R, Croft RA, Dishington AP, Gingipalli L, Gu C, Hawkins JL, Holmes JL, Howard T, et al. Pyrimidinone nicotinamide mimetics as selective tankyrase and wnt pathway inhibitors suitable for in vivo pharmacology. ACS Med Chem Lett. 2015; 6:254-259.
18. Donigian JR, de Lange T. The role of the poly(ADP-ribose) polymerase tankyrase1 in telomere length control by the TRF1 component of the shelterin complex. The Journal of biological chemistry. 2007; 282:22662-22667.
19. Seimiya H, Muramatsu Y, Ohishi T, Tsuruo T. Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics. Cancer cell. 2005; 7:25-37.
20. Hsiao SJ, Smith S. Tankyrase function at telomeres, spindle poles, and beyond. Biochimie. 2008; 90:83-92.
21. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B, Clevers H. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/-colon carcinoma. Science. 1997; 275:1784-1787.
22. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 1997; 275:1787-1790.
23. Segditsas S, Tomlinson I. Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene. 2006; 25:7531-7537.
24. Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nature reviews Cancer. 2013; 13:11-26.
25. Arcaroli JJ, Tai WM, McWilliams R, Bagby S, Blatchford PJ, Varella-Garcia M, Purkey A, Quackenbush KS, Song EK, Pitts TM, Gao D, Lieu C, McManus M, et al. A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer. International journal of cancer. 2016; 138:195-205.
26. Song EK, Tai WM, Messersmith WA, Bagby S, Purkey A, Quackenbush KS, Pitts TM, Wang G, Blatchford P, Yahn R, Kaplan J, Tan AC, Atreya CE, et al. Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model. International journal of cancer. 2015; 136:1967-1975.
27. Arques O, Chicote I, Puig I, Tenbaum SP, Argiles G, Dienstmann R, Fernandez N, Caratu G, Matito J, Silberschmidt D, Rodon J, Landolfi S, Prat A, et al. Tankyrase inhibition blocks Wnt/beta-catenin pathway and reverts resistance to PI3K and AKT inhibitors in the treatment of colorectal cancer. Clin Cancer Res. 2016; 22:644-56.
28. Xu Y, Villalona-Calero MA. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Annals of oncology. 2002; 13:1841-1851.
29. Adamsen BL, Kravik KL, De Angelis PM. DNA damage signaling in response to 5-fluorouracil in three colorectal cancer cell lines with different mismatch repair and TP53 status. International journal of oncology. 2011; 39:673-682.
30. Chikazawa N, Tanaka H, Tasaka T, Nakamura M, Tanaka M, Onishi H, Katano M. Inhibition of Wnt signaling pathway decreases chemotherapy-resistant side-population colon cancer cells. Anticancer research. 2010; 30:2041-2048.
31. Gurney A, Axelrod F, Bond CJ, Cain J, Chartier C, Donigan L, Fischer M, Chaudhari A, Ji M, Kapoun AM, Lam A, Lazetic S, Ma S, et al. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109:11717-11722.
32. Cleveland DW. NuMA: a protein involved in nuclear structure, spindle assembly, and nuclear re-formation. Trends in cell biology. 1995; 5:60-64.
33. Compton DA, Cleveland DW. NuMA, a nuclear protein involved in mitosis and nuclear reformation. Current opinion in cell biology. 1994; 6:343-346.
34. Chang P, Coughlin M, Mitchison TJ. Tankyrase-1 polymerization of poly(ADP-ribose) is required for spindle structure and function. Nature cell biology. 2005; 7:1133-1139.
35. Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C, Shi C, Danenberg K, Danenberg PV, Kuramochi H, Tanaka K, Singh S, Salimi-Moosavi H, et al. An in vivo platform for translational drug development in pancreatic cancer. Clinical cancer research. 2006; 12:4652-4661.
36. Dangles-Marie V, Pocard M, Richon S, Weiswald LB, Assayag F, Saulnier P, Judde JG, Janneau JL, Auger N, Validire P, Dutrillaux B, Praz F, Bellet D, et al. Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features. Cancer research. 2007; 67:398-407.
37. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, Arcaroli JJ, Messersmith WA, Eckhardt SG. Patientderived tumour xenografts as models for oncology drug development. Nature reviews Clinical oncology. 2012; 9:338-350.